Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials
Background: We aimed to systematically assess a possible association of tofacitinib therapy with cardiovascular events (CVEs) and all-cause mortality. Methods: Systematic searches of PubMed, Embase, and Cochrane Library were conducted from inception through March 2019. Randomized controlled trials i...
Main Authors: | Wenhui Xie, Shiyu Xiao, Yanrong Huang, Xiaoying Sun, Zhuoli Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-12-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X19895492 |
Similar Items
-
Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis
by: Wanting Wang, et al.
Published: (2021-09-01) -
Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis
by: Ying Jing, et al.
Published: (2021-03-01) -
Serum IL8 is not associated with cardiovascular events but with all-cause mortality
by: Ilais Moreno Velásquez, et al.
Published: (2019-02-01) -
White Meat Consumption, All-Cause Mortality, and Cardiovascular Events: A Meta-Analysis of Prospective Cohort Studies
by: Roberta Lupoli, et al.
Published: (2021-02-01) -
Prediction model for cardiovascular events or all-cause mortality in incident dialysis patients.
by: Daijo Inaguma, et al.
Published: (2019-01-01)